Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.

MLA

Lockshin, Benjamin, et al. “Drug Survival of Ixekizumab, TNF Inhibitors, and Other IL-17 Inhibitors in Real-World Patients with Psoriasis: The Corrona Psoriasis Registry.” Dermatologic Therapy, vol. 34, no. 2, Mar. 2021, p. e14808. EBSCOhost, https://doi.org/10.1111/dth.14808.

APA

Lockshin, B., Cronin, A., Harrison, R. W., McLean, R. R., Anatale-Tardiff, L., Burge, R., Zhu, B., Malatestinic, W. N., Atiya, B., Murage, M. J., Gallo, G., Strober, B., & Van Voorhees, A. (2021). Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy, 34(2), e14808. https://doi.org/10.1111/dth.14808

Chicago

Lockshin, Benjamin, Angel Cronin, Ryan W Harrison, Robert R McLean, Laura Anatale-Tardiff, Russel Burge, Baojin Zhu, et al. 2021. “Drug Survival of Ixekizumab, TNF Inhibitors, and Other IL-17 Inhibitors in Real-World Patients with Psoriasis: The Corrona Psoriasis Registry.” Dermatologic Therapy 34 (2): e14808. doi:10.1111/dth.14808.